CSL Stock News

CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kid...

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-...

Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud ​arm to harness AI and cloud ‌technology across its research and clinical development pipeline.

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.

The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said

Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.

U.S. President Donald ​Trump is expected to announce a new round of drug-pricing agreements on Monday, a White ‌House official said, part of a push to make healthcare more affordable for Americans.